je.st
news
Tag: pfizer
Pfizer jobs at risk over UK sites closure plan
2016-11-09 11:02:33| BBC News | Business | UK Edition
More than 370 jobs are at risk after the US drugs giant Pfizer announces plans to shut two of its UK sites.
EPA Fines Pfizer For Violations At Puerto Rico Facility
2016-10-28 07:16:00| Chemical Processing
The agency fines Pfizer $190,000 for failing to disclose hazardous substances.
Tags: rico
facility
puerto
fines
Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
2016-09-15 14:31:48| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J., and NEW YORK, N.Y. New Phase 3 Data Presented at the European Association for the Study of Diabetes Annual Meeting Study Achieved Primary and All Key Secondary Endpoints KENILWORTH, N.J., and NEW YORK, N.Y. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint. Language: English read more
Pfizer and Medivation reportedly close to $14bn deal
2016-08-22 03:02:09| BBC News | Business | UK Edition
US pharmaceutical giant Pfizer is reportedly in advanced talks to buy cancer drug firm Medivation for about $14bn (10.7bn).
Tags: close
deal
reportedly
pfizer
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
2016-06-11 17:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & NEW YORK Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). Language: English Contact: Merck Media Contacts:Doris Li, 908-246-5701orKristen Drake, 908-334-4688orMerck Investor Contact:Justin Holko, 908-740-1879orPfizer Media Contact:Steve Danehy, 212-733-1538orPfizer Investor Contact:Ryan Crowe, 212-733-8160 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: PFE Exchange: NYSE read more
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »